Linked Life Data

15713900

Source:http://linkedlifedata.com/resource/pubmed/id/15713900

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15713900rdf:typepubmed:Citationlld:pubmed
pubmed-article:15713900lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15713900lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:15713900lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:15713900lifeskim:mentionsumls-concept:C0038792lld:lifeskim
pubmed-article:15713900lifeskim:mentionsumls-concept:C1366521lld:lifeskim
pubmed-article:15713900lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:15713900lifeskim:mentionsumls-concept:C1510800lld:lifeskim
pubmed-article:15713900pubmed:issue2lld:pubmed
pubmed-article:15713900pubmed:dateCreated2005-2-16lld:pubmed
pubmed-article:15713900pubmed:abstractTextSeveral studies have shown antitumor activities of the melanoma differentiation-associated gene 7 (mda-7) and the nonsteroidal anti-inflammatory drug sulindac when used as a monotherapies against a wide variety of human cancers. However, the combined effects of mda-7 and sulindac have not previously been tested. Therefore, we tested the antitumor activity of an adenoviral vector expressing mda-7 (Ad-mda7) in combination with sulindac against non-small cell lung cancer cells in vitro and in vivo. When treated with Ad-mda7 in combination with sulindac, human lung cancer cells (A549 and H1299) underwent growth suppression resulting in apoptosis. The growth inhibition induced by Ad-mda7 in combination with sulindac was significantly greater than that observed with Ad-mda7 or sulindac alone. Furthermore, the degree of growth inhibition induced using this combination was dose-dependent for sulindac. Treatment with Ad-mda7 in combination with sulindac had no growth inhibitory effects on human normal lung (CCD-16) fibroblasts. We then investigated the mechanism by which sulindac enhances Ad-mda7-mediated apoptosis. Sulindac increased expression of ectopic MDA-7 protein in tumor cells, thereby increasing the expression of downstream effectors RNA-dependent protein kinase, p38MAPK, caspase-9, and caspase-3 and enhancing apoptosis of non-small cell lung cancer cells. Pulse-chase experiments showed that the increased expression of MDA-7 protein in sulindac-treated cells was due to increased half-life of the MDA-7 protein. Finally, treatment of human lung tumor xenografts in nude mice with Ad-mda7 plus sulindac significantly suppressed growth (P = 0.001) compared with Ad-mda7 or sulindac alone. Our results show for the first time that combined treatment with Ad-mda7 plus sulindac enhances growth inhibition and apoptosis of human lung cancer cells. The increased antitumor activity observed with the combination treatment is a result of increased half-life of MDA-7 protein. Regulation of protein turnover is a heretofore-unrecognized mechanism of this nonsteroidal anti-inflammatory drug.lld:pubmed
pubmed-article:15713900pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:languageenglld:pubmed
pubmed-article:15713900pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:citationSubsetIMlld:pubmed
pubmed-article:15713900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15713900pubmed:statusMEDLINElld:pubmed
pubmed-article:15713900pubmed:monthFeblld:pubmed
pubmed-article:15713900pubmed:issn1535-7163lld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:LiuLLlld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:RothJack AJAlld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:BekeleB...lld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:MiyaharaRyoRlld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:InoueSatoshiSlld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:ChadaSunilSlld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:MhashilkarAbn...lld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:BranchCynthia...lld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:RameshRajagop...lld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:OidaYasuhisaYlld:pubmed
pubmed-article:15713900pubmed:authorpubmed-author:BeganGopalanGlld:pubmed
pubmed-article:15713900pubmed:issnTypePrintlld:pubmed
pubmed-article:15713900pubmed:volume4lld:pubmed
pubmed-article:15713900pubmed:ownerNLMlld:pubmed
pubmed-article:15713900pubmed:authorsCompleteYlld:pubmed
pubmed-article:15713900pubmed:pagination291-304lld:pubmed
pubmed-article:15713900pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:meshHeadingpubmed-meshheading:15713900...lld:pubmed
pubmed-article:15713900pubmed:year2005lld:pubmed
pubmed-article:15713900pubmed:articleTitleSulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer.lld:pubmed
pubmed-article:15713900pubmed:affiliationDepartment of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Unit 445, 1515 Holcombe Boulevard, Houston, TX 77030, USA.lld:pubmed
pubmed-article:15713900pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15713900pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15713900pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15713900pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15713900lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15713900lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15713900lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15713900lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15713900lld:pubmed